{
  "id": 15805058,
  "title": "ESCRT-dependent YAP degradation by AKT blockade overcomes adaptive resistance to RAS(ON) inhibition in pancreatobiliary cancer",
  "url": "https://urgent.news/2026/10/20/escrt-dependent-yap-degradation-by-akt-blockade-overcomes-adaptive",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-20T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.10.18.759975v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Adaptive YAP/TAZ activation limits durable responses to RAS pathway inhibition in pancreatobiliary cancers. We identify AKT as a regulator of YAP protein stability and define a non-canonical, therapeutically actionable ESCRT-dependent lysosomal degradation pathway. Capivasertib, an FDA-approved pan-AKT inhibitor, triggered post-translational YAP degradation by 12 hours, routing YAP to ESCRT…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}